Outsourcing Pharma

NOVEMBER 16, 2021

have received the green light from Health Canada for their Clinical Trial Application for VCTX210: an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D). CRISPR Therapeutics and ViaCyte, Inc.

Diabetes 111

Diabetes Immunity Immunization 111

STAT

MAY 10, 2023

The institute will be led by Brigham immunologist and principal investigator Vijay Kuchroo, who will lead teams dedicated to studying chronic inflammation and discovering drugs for conditions associated with it, such as food allergies and type 1 diabetes. Continue to STAT+ to read the full story…

Immunity 235

Immunity Immunization Hospitals Diabetes 235

STAT

NOVEMBER 21, 2023

Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes. Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age.

Diabetes 250

Diabetes Immunity Immunization 250

pharmaphorum

MARCH 11, 2021

Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and genetic therapies – and has just chalked up fast-track status from the FDA for a cell-based therapy for diabetes. . The aim is to replace the pancreatic tissue that is damaged by the autoimmune reaction that underlies type 1 diabetes.

Diabetes 98

Diabetes Immunity Immunization 98

STAT

FEBRUARY 28, 2024

vaccination policy when Mandy Cohen, director of the Centers for Disease Control and Prevention, signs off on the recommendation from the Advisory Group on Immunization Practices. Babies infected around the time of birth, adults 65 and older and people with heart disease, diabetes or high blood pressure are at higher risk of severe disease.

Vaccines 273

Vaccines Diabetes Immunity Immunization 273

pharmaphorum

NOVEMBER 18, 2022

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease-modifying therapy for these patients. The post Provention finally gets FDA nod for type 1 diabetes drug teplizumab appeared first on.

Diabetes 52

Diabetes Immunity Immunization 52

pharmaphorum

JULY 11, 2022

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The post Vertex buys diabetes cell therapy rival ViaCyte for $320m appeared first on.

Diabetes 58

Diabetes Immunity Immunization 58

NY Times

NOVEMBER 27, 2021

A new treatment using stem cells that produce insulin has surprised experts and given them hope for the 1.5 million Americans living with the disease.

Diabetes 145

Diabetes Immunity Immunization 145

Express Pharma

APRIL 7, 2023

The findings, published in the journal Environmental Health Perspectives , provide further evidence on the adverse effects of air pollution on the immune system. However, the role of long-term exposure to air pollution on hybrid immunity (infection plus vaccination) deserves further investigation, they added.

Vaccines 100

Vaccines Immunity Immunization Diabetes 100

Digital Pharmacist

JANUARY 16, 2023

From cancer prevention to diabetes awareness, these events help bring communities together. World Immunization Week: April 24-30. National Immunization Awareness Month. National Diabetes Month. World Immunization Week | Post a flyer and share a list on social media of your vaccination offerings. . UV Safety Month.

Immunity 98

Immunity Immunization Vaccines Diabetes 98

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function.

Diabetes 95

Diabetes Labelling Immunity Immunization 95

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function.

Diabetes 94

Diabetes Labelling Immunity Immunization 94

pharmaphorum

AUGUST 17, 2020

Phase 3 development in the bleeding disease thrombocytopenia is expected to begin by the end of the year as long as COVID-19 does not impact on trials and there is also an ongoing phase 2 development programme in various other immune diseases.

Immunity 124

Immunity Immunization Diabetes 124

Pharmacy Times

DECEMBER 20, 2022

Associated postherpetic neuralgia risk factors are history of diabetes mellitus, age, and immune-related disease.

Diabetes 29

Diabetes Immunity Immunization 29

The Thyroid Pharmacist

SEPTEMBER 2, 2022

A review paper published in 2010 that discussed the relationship between thyroid dysfunction and metabolic disorders, highlighted the fact that patients with diabetes were up to three times more likely to develop a thyroid disorder. (7). Hypoglycemia is an early risk factor for developing diabetes. Type 2 Diabetes.

Diabetes 98

Diabetes Health and Personal Care Stores Immunity Immunization 98

PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

Diabetes 64

Diabetes Immunity Immunization Biosimilars 64

Express Pharma

APRIL 24, 2023

Adults above 50 years of age and those suffering from chronic conditions such as diabetes, heart disease and kidney diseases are at an increased risk of developing shingles because of weakened immunity. Vaccination is the only effective preventive option.”

Vaccines 86

Vaccines Diabetes Immunity Immunization 86

pharmaphorum

JANUARY 11, 2021

Cambridge-based Kymab is one of several rising stars on the UK biotech scene, with technology that uses transgenic mice to develop antibodies optimised for the human immune system. KY1005 works by bonding to the OX40-Ligand (OX40-L), which forms an important part of the process that activates the immune system.

Immunity 70

Immunity Immunization Diabetes Vaccines 70

Pharmaceutical Technology

OCTOBER 25, 2022

As proof-of-concept (PoC), chronic immune-mediated diseases such as atopic dermatitis (AD) and inflammatory bowel disease (IBD) will be the focus areas of the preliminary model. For the project, deep datasets and capabilities of Sanofi will be leveraged to potentially transform the practice of medicine using digital data and AI.

Drug Development 98

Drug Development Diabetes Immunity Immunization 98

pharmaphorum

JUNE 1, 2021

Novo Nordisk – which is already active in stem cell therapies with a candidate in early development for type 1 diabetes – is on the hook for up to $598 million in total licensing and milestone payments plus royalties on sales if HS-001 reaches the market.

Immunity 138

Immunity Immunization Diabetes 138

pharmaphorum

NOVEMBER 12, 2021

It also takes into account existing and chronic health factors such as diabetes, obesity, and conditions that affect the immune system can play a big role in risk factors related to COVID-19.

Diabetes 135

Diabetes Immunity Immunization 135

Putting Patients First Blog

DECEMBER 18, 2023

Schubert , President & CEO, Society for Women’s Health Research Michael Ybarra , MD , Chief Medical Officer, PhRMA Sunita Mishra , MD , Chief Medical Officer, Amazin Health Services Michele M.

Diabetes 52

Diabetes Communication Immunity Immunization 52

Pharmaceutical Technology

APRIL 3, 2023

The latest guidance applies to the current phase of the pandemic and reflects the impact of the Omicron variant, which has led to high levels of immunity in all age groups through both vaccination efforts and infections across the globe.

Vaccines 111

Vaccines Diabetes Immunity Immunization 111

Pharmaceutical Technology

MAY 31, 2023

It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions.

Diabetes 52

Diabetes Immunity Immunization Hospitals 52

Big Molecule Watch

SEPTEMBER 25, 2023

YESAFILI is intended for the treatment of neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV).

Biosimilars 57

Biosimilars Diabetes Immunity Immunization 57

pharmaphorum

FEBRUARY 10, 2022

In its annual results statement, AZ said that it took the decision on the back of data showing that a third dose of Vaxzevria increased the immune response to new variants, including Omicron which is currently driving new COVID-19 cases around the world. ” Vaxzevria added almost $4 billion to its revenues last year, including $1.8

Vaccines 52

Vaccines Immunity Immunization Diabetes 52

pharmaphorum

JANUARY 17, 2022

It prevents the overstimulation of the immune system and is said to improve survival and reduce the need for ventilation in covid-19 patients, with no observed increase in adverse effects. Baricitinib, administered with corticosteroids, was strongly recommended as a treatment for patients with severe or critical illness.

Hospitals 115

Hospitals Diabetes Immunity Immunization 115

pharmaphorum

MAY 6, 2021

Israeli company Kadimastem is developing regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells to treat diseases such as Amyotrophic lateral sclerosis (ALS) and diabetes. Catherine Longworth spoke with Kadimastem’s head of diabetes research, Kfir Molakandov to find out more.

Diabetes 126

Diabetes Immunity Immunization 126

Pharmaceutical Technology

JUNE 12, 2023

The partnership will use Quell’s toolbox of Treg cell engineering modules, which includes the Foxp3 phenotype lock, to create autologous multi-modular Treg cell therapy candidates to treat Type 1 diabetes (T1D) and inflammatory bowel disease (IBD).

Immunity 52

Immunity Immunization Diabetes 52

Digital Pharmacist

JULY 11, 2023

Immunizations & Vaccinations Independent pharmacies are ideally positioned to provide convenient immunization services to their communities. Chronic Disease Management Independent pharmacies can play a crucial role in managing chronic diseases such as diabetes, hypertension, and asthma.

Independent Pharmacies 98

Independent Pharmacies Medication Therapy Management (MTM) Compounding Scheduling Appointments 98

Board Vitals - Pharmacist

JANUARY 11, 2024

Complete a state-mandated number of hours as a pharmacy intern Some pharmacists become certified in specialty areas such as immunization, diabetes education, nutrition or oncology. Licensing boards for these specialties vary.

Retail Drug Stores 98

Retail Drug Stores Hospitals Doctor of Pharmacy Dosage 98

RX Note

APRIL 21, 2023

Lack of sleep can increase the risk of chronic diseases , such as coronary heart disease, hypertension, stroke, obesity, diabetes as well as weakened immune system. Mental Health Sleep helps with learning and the formation of long-term memories.

Diabetes 52

Diabetes Immunity Immunization 52

The Thyroid Pharmacist

OCTOBER 7, 2022

I knew he was right — sugar can contribute to a yeast overgrowth, lowered immunity, blood sugar issues, weight gain, diabetes, and a whole host of health problems (1-3) — but I was a sugar addict, and it was devastating to think that I would have to let go of this old friend and not have any sweetness in my life.

Diabetes 92

Diabetes Immunity Immunization Labelling 92

Pharmaceutical Technology

MAY 15, 2023

ViaCyte, formerly Novocell and is now being acquired by Vertex, is a regenerative medicine company developing novel cell replacement therapies for the treatment of diabetes to achieve glucose control targets and reduce the risk of hypoglycaemia and diabetes-related complications.

Diabetes 52

Diabetes Hospitals Immunity Immunization 52

PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

Diabetes 40

Diabetes Immunity Immunization Biosimilars 40

Pharmaceutical Technology

JANUARY 10, 2023

On November 17, 2022, the FDA approved Provention Bio’s Tzield (teplizumab) , making it the first and only treatment to delay the onset of type 1 diabetes (T1D). Tzield’s approval brings the opportunity to explore how the drug can advance diabetes education, treatment, and management. “We Equity in early-stage testing.

Diabetes 98

Diabetes Immunity Immunization Communication 98

Express Pharma

SEPTEMBER 12, 2023

tumor formation, immune reactions, and therapy failure). tumor formation, immune reactions, and therapy failure). As such, it is unsurprising that a stem cell therapy is being considered for the treatment of DC due to NASH.

Diabetes 110

Diabetes Immunity Immunization 110